GBG at ESMO 2026 in Madrid

 

GBG Participation at ESMO 2026 in Madrid

This year, GBG is once again contributing to the presentation of new scientific findings.

 

Poster Presentation:“Stereotactic Radiosurgery (SRS) and Radiotherapy in Breast Cancer Brain Metastases (BCBM): Subtype-Specific Analysis of the BMBC Registry”

Presented by: Raphael Bodensohn

Presentation: October 24, 2026, 12:00–12:45 p.m., Poster Area – Hall 5

Poster download will be available soon.

 

Further Contributions Involving GBG

 

  • Educational Session: Optimising Treatment for HER2+ Early Breast Cancer

What to do after optimal neoadjuvant therapy?

Presenting author: Sibylle Loibl

Presentation: October 25, 2026, 11:15–11:35 a.m., Barcelona Auditorium – Hall 9

 

  • DESTINY-Breast09

DB-09 – A DESTINY-Breast (DB-)09 analysis of trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC) and baseline (BL) brain metastases (BMs) (LBA49)

Presenting author: Cristina Saura Manich

Presentation: October 26, 2026, 10:15–11:45 a.m., Alicante Auditorium – Hall 6

 

  • DESTINY-Breast05

Patient-Reported Outcomes (PROs) From DESTINY-Breast05: Health-Related Quality of Life (HRQoL) With Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Patients (Pts) With High-Risk HER2-Positive Early Breast Cancer (eBC) (538RO)

Presenting author: Gustavo Werutsky

Presentation: October 23, 2026, 4:15–5:45 p.m., Alicante Auditorium – Hall 6

 

  • PANTHER

Independent validation of an AI-based prognostic assay in clinically high-risk ER+/HER2- early breast cancer: Results from the phase III PANTHER trial (551P)

Presenting author: Ioannis Zerdes

Presentation: October 24, 2026, 12:00–12:45 p.m., Poster Area – Hall 5

 

Further Contributions by Our Subboard Members

 

  • Vesna Bjelic-Radisic

Rapid Oral 1 and Invited Discussant: Breast Cancer, Advanced Stage

Presentation: October 24, 2026, 11:09–11:21 a.m., Almeria Auditorium – Hall 9

 

  • Thomas Decker

Poster: Advanced Breast Cancer, Other

Clinical characteristics and outcomes of endocrine-resistant hormone receptor positive, HER2-negative (HR+/HER2−) advanced breast cancer: Insights from the AGO-B CAPTOR trial (16P)

Presentation: October 24, 2026, 12:00–12:45 p.m., Poster Area – Hall 5

 

  • Carsten Denkert

Special Symposium: Incorporation of Biomarkers for Early Breast Cancer

Dynamic tissue-based biomarkers to guide treatment

Presentation: October 26, 2026, 2:45–3:05 p.m., Almeria Auditorium – Hall 9

 

  • Peter A. Fasching

1. Industry Satellite Symposium: Answers in CME – Building a Bridge From Evidence to Practice: Case Discussion of First-Line Treatment of HER2-Positive mBC

Presentation: October 25, 2026, 1:00–2:30 p.m., Malaga Auditorium – Hall 3

2. Industry Satellite Symposium: Novartis – From Risk to Recurrence: Personalizing CDK4/6 Inhibitor Strategies in HR+/HER2− Breast Cancer

Presentation: October 26, 2026, 1:00–2:30 p.m., Madrid Auditorium – Hall 4

Poster: Breast Cancer, Early Stage

3. Health-related quality of life (HRQoL) in patients (pts) with HR+/HER2− early breast cancer (EBC) receiving adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone: 5-y NATALEE subgroup analyses by nodal status and stage (581P)

Presentation: October 24, 2026, 12:00–12:45 p.m., Poster Area – Hall 5

4. Proffered Paper 2: Breast Cancer, Early and Advanced Stage

Presentation: October 24, 2026, 9:00–9:10 a.m., Alicante Auditorium – Hall 6

 

  • Athina Kostara

Poster: Supportive Care

Scalp cooling meaningfully reduces chemotherapy-induced alopecia (CIA): Real-world evidence from a 500-breast cancer patient cohort (3995P)

Presentation: October 24, 2026, 12:00–12:45 p.m., Poster Area – Hall 5

 

  • Frederik Marmé

1. Educational Session: Update on the Management of Endometrial Cancer in the Era of Molecular Classification

Current evidence and development of ADCs in EC

Presentation: October 23, 2026, 2:10–2:30 p.m., Murcia Auditorium – Hall 3

2. Industry Satellite Symposium: AbbVie – Riding the Wave of Innovation Towards Personalized Medicine in Ovarian Cancer

New ADC Horizons: Sequencing Strategies, Emerging Therapies, and the Next Frontier in Ovarian Cancer

Presentation: October 23, 2026, 10:25–10:50 a.m., Leon Auditorium – Hall 4

3. Poster: Gynaecological Cancers

AGO OVAR 27, a non-randomised phase II window-of-opportunity (WoO) trial of olaparib (Ola) alone (cohort A) or in combination with durvalumab (cohort B) prior to primary debulking surgery (PDS) in high-grade ovarian cancer (OC): Primary results of cohort (1267P)

Presentation: October 26, 2026, 12:00–12:45 p.m., Poster Area – Hall 5

 

  • Volkmar Müller

Industry Satellite Symposium: Pfizer Oncology – Metastatic Breast Cancer: Individualised Decision-Making in Focus

Presentation: October 25, 2026, 6:30–8:00 p.m., Madrid Auditorium – Hall 4

 

  • Marc Thill

Poster: HR+ Breast Cancer

Optimal treatment strategies following first-line CDK4/6 inhibitor in HR+ HER2- metastatic breast cancer: Real-world evidence from the OPAL registry platform (1876P)

Presentation: October 24, 2026, 12:00–12:45 p.m., Poster Area – Hall 5